Jason Lettmann, Lightstone Ventures
September 14, 2021 07:00 AM EDT
Financing

Light­stone Ven­tures un­veils $375M third fund, this time ex­pand­ing its wish­list in blos­som­ing CNS field

Kyle Blankenship

Neu­ro­science is hav­ing a mo­ment right now, and one VC firm strad­dling the line be­tween biotech and medtech is look­ing to cap­i­tal­ize on the field’ …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Trump ad­min­is­tra­tion re­veals 'most fa­vored na­tion' drug price coun­try tar­gets

Makary, Prasad spell out FDA ground rules for fu­ture Covid vac­cine ap­provals

End­points 100 biotech sur­vey: Wel­come to the sum­mer of biotech’s dis­con­tent

Why Re­gen­eron is buy­ing 23andMe

Pfiz­er joins PD-1xVEGF race with $1.25B up­front to Chi­nese biotech 3SBio

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times